Ignite Creation Date:
2024-05-05 @ 7:23 PM
Last Modification Date:
2024-10-26 @ 9:48 AM
Study NCT ID:
NCT00669786
Status:
COMPLETED
Last Update Posted:
2008-05-01
First Post:
2008-04-29
Brief Title:
Human Menopausal Gonadotropin HMG vs Recombinant Follicle Stimulating Hormone rFSH in Gonadotropin Releasing Hormone GnRH Antagonist Cycles
Sponsor:
Instituto Valenciano de Infertilidad IVI VALENCIA
Organization:
Instituto Valenciano de Infertilidad IVI VALENCIA
Study Overview
Official Title:
Highly Purified Human Menopausal Gonadotropin Versus Recombinant Follicle Stimulating Hormone in Ovarian Hyperstimulation With Gonadotropin Releasing Hormone Antagonists A Randomized Study
Status:
COMPLETED
Status Verified Date:
2008-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A randomized controlled trial comparing the ongoing pregnancy rate primary end-point in 280 patients undergoing IVFICSI after stimulation with hp-hMG or rFSH controlled with a GnRH antagonist Non significant differences were observed between hp-hMG and rFSH in terms of the ongoing pregnancy rate per started cycle 350 vs 321 p061 RR 109 95 CI 078-151 Risk Difference 29 No differences were observed for implantation clinical pregnancy and pregnancy loss rates Patients receiving rFSH obtained more oocytes 144 81 vs 113 60 p0001 Estradiol was higher at the end of stimulation in the hp-hMG group while Progesterone was higher in patients stimulated with rFSH
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None